This study collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.
PRE-REGISTRATION ELIGIBILITY CRITERIA: Planning to receive a regimen containing one or more IO therapeutics
PRE-REGISTRATION ELIGIBILITY CRITERIA: Has not previously been treated with CTLA-4, PD-1 or PD-L1 inhibitors
PRE-REGISTRATION ELIGIBILITY CRITERIA: Willing and able to provide baseline blood and stool samples
REGISTRATION ELIGIBILITY CRITERIA: Received a regimen containing one or more immuno-oncology therapeutics
None
Patients who have received one or more immuno-oncology therapeutics and experienced one or more serious adverse events (AEs)
Cohort
Prospective
Biospecimen Collection
Procedure/SurgeryUndergo collection of tissue, blood, and stool samples
Medical Chart Review
Other interventionReview of medical records
Establishment of a national biorepository including biospecimen and clinical data collections for future use
The objective of this study to establish a biorepository of biospecimen and clinical data. There is no primary clinical outcome for this study.
Click on the lead sponsor to view all of their trials.
Alliance for Clinical Trials in Oncology
Lead sponsor
National Cancer Institute (NCI)
Collaborator
